Medical Analysis

Comprehensive Medical Guide to Triple Marker Test in Pregnancy: Clinical Pathways, Laboratory Diagnostic Protocols, and Advanced Pathophysiology

Advanced Clinical Introduction to Triple Marker Screening and Fetal Chromosomal Abnormalities

The Triple Marker Test, also known as the triple screen test, is a vital prenatal screening test used to assess the risk of certain genetic disorders and birth defects in a developing foetus [3]. This non-invasive test measures the levels of three substances in the mother’s blood: Alpha-Fetoprotein, Human Chorionic Gonadotropin and Unconjugated Estriol [3, 8]. This test is advised to all pregnant women, especially if they report: Family history of genetic problems [11]. It carries 70% sensitivity and 5% false positivity rates [8].

Detailed Pathophysiology of Assay Substances and Associated Markers

During interpretation of the results; age of the mother, weight & ethnicity must be considered [5, 9]. These markers help in assessing the risk of the fetus having chromosomal abnormalities eg. Down’s Syndrome, Neutral Tube Defect [1, 3, 8].

Comprehensive Clinical Diagnostic Criteria and Laboratory Workup Frameworks

Clinical Protocol for Managing the Triple Marker Test Procedure

It is performed between 14 – 18 weeks of pregnancy [8].

What is required to interpret the report of Triple Marker Screen?

• Sonography report of anomaly scan with age of gestation [4, 8].

• Height, Weight & Ethnicity [5, 9].

• Date of Birth [8]

• LMP [8]

Clinical Management and Execution Protocol

Get done this test between 14th and 18th weeks of pregnancy [8]. It is advisable especially for those pregnant women; who are having family history of genetic issues, diabetic and age 35 years or above, to get this done [1, 11]. Discuss in details with patient. i.e. Purpose of the test, benefits and potential risk of results [1]. Ultrasound examination reports are must [4, 8]. This test does not provide definite diagnosis but shows a risk in proportion for chromosomal abnormalities [1, 3]. Your doctor may recommend further tests like amniocentesis to confirm suspected abnormalities [2]. Genetic counseling for implications of findings [2, 11].

Role of Ultrasound Examination and Clinical Significance

Triple Marker Screen points towards Down’s Syndrome or neural tube defects [1, 3, 8]. However; for detecting physical anomalies like cardiac structural defects, brain anomalies or defects in various other organs; anomaly scan always remains a choice; which also helps to correlate results [4, 8]. To confirm gestational age : Accurate dating possible [4, 8]. To detect any other gross structural abnormality [4, 8]. Assesses in calculating combined risk for chromosomal abnormalities [4, 8]. Helps in comprehensive genetic counseling and explaining implications of the screening results [2, 4].

Clinical Indications, Analytical Methodology, and Specimen Protocols

Sample Collection, Preparation, Clinical Data Requirements, and Stability

Collect 3.0 ml blood in plain tube (Red capped) [8]. Separate serum as early as possible and send to lab along with following information [8]. Patient’s date of birth, weight and LMP [8]. Ultrasound anomaly scan report along with fetus age [4, 8].

Assay Methods & Reference Range

Refer ppts of hCG, AFP & uE3 (Unconjugated estriol) [8].

Responsibility of Doctor to Provide Following Information

• Weight (kgs) & Height (cms) of patient [5, 9].

• History of previous pregnancy helps to assess the risk [3, 8].

• Things which can cause changes the hormonal levels; eg. Diabetes, HCG injections or any other medications [8].

• For IVF conception; risk assessment is related with Date of Birth of Donor [8].

• Accurate Ultrasound report is must [4, 8]. Total sensitivity and accuracy of the test results vary with ultrasound report [4, 8].

Purpose of Triple Marker Test

It is calculated by combining the biochemical results obtained (values of hCG, AFP & uE3) with the patient’s information along with sonography anomaly scan report [4, 8]. The triple marker test primarily screens for major genetic issues in the fetus, such as:

• Down’s syndrome – Caused by an extra copy of chromosome 21 [1, 3]

• Neural tube defects – When the spinal cord or brain fails to develop properly [3, 8]

• Edwards syndrome (Trisomy 18) – Extra chromosome 18 [3]

• Trisomy 13 (Patau syndrome) – Extra chromosome 13 The test calculates, based on maternal blood markers, whether the fetus falls into a high or low-risk zone for these common chromosomal issues [3, 8].

How Triple Marker Test Helps?

Software calculates the risk probabilities based on the hormone levels [8]. Results indicate high or low chances of genetic issues [1, 3, 8]. If high risk, further invasive testing is suggested to confirm diagnosis [2, 3].

Uses of Triple Test Screen

May become vigilant for additional prenatal diagnostic testing [2, 8]. Warning signal passes to parents and get mentally prepared for high-risk pregnancy; including forthcoming genetic abnormalities [1, 3]. Doctor and parents both become ready for pregnancy intervention during [3, 8].

Reference Ranges and Multiples of Median (MoM) Frameworks

MoM (Multiple of Median) Definition and Calculation

Multiple if Median: When multiple parameters show results deviating from their median value [8].

MoM (Multiple of Median) calculation formula: Patient’s Results divided by the Median Value for Gestational Age [8].

Median Value for Gestational Age: It is calculated by taking mean from the reference population for the same gestational age [8].

Normal Reference Range

Triple Marker Screen – Importance of Assays

Comments & Limitations

Parents must be informed about test platform, software used and disclaimers associated with screening test [3, 8]. Essential to know that this is a simple screening test and it does not offer any concrete diagnosis [1, 3, 8]. It only suggests risk associated with pregnancy [3, 8]. It facilitates doctor to decide for additional tests for further evaluation or confirmation [2, 3]. Negative test result does not guarantee absolute healthy baby [3, 8].

For Non-Medicos

What Is A Triple Marker Test?

A simple and safe blood test done during pregnancy to check if the baby has any risks for genetic disorders [3, 8].

Simple Guide to Symptoms, Testing, and Care

• Performed between weeks 14 and 18 of pregnancy [8].

• Measures three specific substances in the mother’s blood (AFP, hCG, and Unconjugated Estriol) [3, 8].

• Helps detect risks for Down’s syndrome, neural tube defects, and other conditions [1, 3, 8].

• Guides doctors on whether further tests, like an amniocentesis, are needed [2, 3].

References:

1. American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 226: Screening for Fetal Chromosomal Abnormalities. Obstet Gynecol. 2020;136(4):e48-e69.

2. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31(1):7-15.

3. Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med. 2005;353(19):2001-2011.

4. Wald NJ, Rodeck C, Hackshaw AK, et al. SURUSS in perspective. Semin Perinatol. 2005;29(4):225-235.

5. Spencer K, Bindra R, Farecq A, et al. First-trimester ultrasound screening for trisomy 21: the effect of nuchal translucency measurement on the detection rate and false-positive rate. Ultrasound Obstet Gynecol. 2003;22(2):147-152.

6. Breathnach FM, Malone FD. Screening for aneuploidy in first and second trimesters: is there an optimal approach? Curr Opin Obstet Gynecol. 2007;19(2):176-182.

7. Cuckle HS, et al. First-trimester maternal serum screening for Down syndrome: a meta-analysis. Prenat Diagn. 2005;25(13):1160-1165.

8. Snijders RJM, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol. 1999;13:167–170.

9. Kagan KO, Wright D, Spencer K, et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol. 2008;31(5):493-502.

10. Wright D, Spencer K, Kagan KO, et al. First-trimester sonographic markers for trisomy 21: a study of 12 188 fetuses. Ultrasound Obstet Gynecol. 2008;32(7):874-880.

11. Wilson RD. Amended Canadian Guideline for prenatal diagnosis (2005) change to 2005—techniques for prenatal diagnosis. SOGC Clinical Practice Guidelines, No. 168. J Obstet Gynaecol Can. 2005;27:1048–1054.

12. The Fetal Medicine Foundation. Screening for chromosomal abnormalities in the first trimester. [Online Resource].

13. Jindal A, et al. Reference Centile Charts of PAPP-A and Free β-hCG in Indian Pregnant Women. Int J Sci Res. 2021.

14. Journal of Surgery and Medicine. The relationship of PAPP-A and ß-HCG values with fetal gender and fetal birth weight: A single-center experience. 2025;9(7):93-97.

15. Journal of Nursing Reports in Clinical Practice. The first-trimester screening to detect chromosomal abnormalities in pregnant women: A retrospective study. 2023.

FAQ’s:

• What is a triple marker test?
  It is a prenatal screening test measuring three blood substances to assess fetal genetic disorder risks.
• When is the test performed?
  The test is conducted between the 14th and 18th weeks of pregnancy.
• What markers are measured?
  The test measures Alpha-Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG), and Unconjugated Estriol (uE3).
• Is it a diagnostic test?
  No, it is a screening test showing relative risk levels, not a definite diagnosis of abnormalities.
• Who should take this test?
  It is advised for pregnant women, particularly those with genetic issues, diabetes, or aged 35-plus.
• What does it help detect?
  It screens for Down’s syndrome, neural tube defects, Edwards syndrome, and Trisomy 13 (Patau syndrome).
• Why is ultrasound needed?
  Ultrasound confirms gestational age and identifies physical anomalies, which are essential for accurate risk calculation.
• What does MoM indicate?
  MoM (Multiple of Median) shows how much a patient’s results deviate from the reference population median.
• What information is required?
  Doctors must provide patient weight, height, LMP, age, and an accurate ultrasound anomaly scan report.

What if risk is high?
High-risk results suggest the need for further diagnostic evaluations, such as amniocentesis, to confirm findings.

 Relate Tests

• Quadruple Marker Test
• Double Marker Test